enGene Holdings Inc. (NASDAQ:ENGNW – Get Free Report)’s stock price traded up 5% on Tuesday . The stock traded as high as $0.48 and last traded at $0.5040. 250 shares changed hands during trading, a decline of 98% from the average session volume of 16,253 shares. The stock had previously closed at $0.48.
enGene Stock Performance
The stock’s 50 day moving average price is $0.30 and its 200-day moving average price is $1.52.
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Further Reading
- Five stocks we like better than enGene
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
